The global liquid biopsy market is anticipated to value over US$ 20 billion by the end of 2033 and expanding at a CAGR of over 18% during the forecast period, 2025 to 2033.  

Cancer is one of the most prevalent diseases owing to which the need for various cancer treatments. Techniques like biopsy are used to understand the tumour nature so that cancer can be managed correctly which can be eliminated eventually. There are two techniques used, one is the conventional method of solid tissue biopsy and other is the newly introduced liquid biopsy technique. Metastatic relapse evaluation and minimal invasiveness are some of the advantages of using liquid biopsy over solid tissue biopsy which would increase its demand resulting in the growth of the market. A further boost to the market growth will be contributed by factors like patient preference to get minimally invasive therapy, increase in the number of cancer cases and increase in the disposable income among patients suffering from cancer. Also, using liquid biopsy tests to identify and treat rare cancers will provide multiple opportunities for key market players to establish and expand their business.  

Insights on Global Liquid Biopsy Market:
By Region
•    North America
•    Europe
•    Asia Pacific
•    Latin America
•    Rest of the World
The North America liquid biopsy market is expected to grow at a CAGR of approximately 11.5% to 19.6% from 2025 to 2033. This growth is driven by a high cancer burden, increasing adoption of non-invasive diagnostics, supportive regulatory policies (including FDA approvals and Medicare coverage), and significant R&D investment by key players like Guardant Health, Exact Sciences, and Natera. The region’s advanced healthcare infrastructure and growing use of liquid biopsies for early detection and treatment monitoring are further accelerating market expansion.

By Circulating Biomarker
•    Circulating tumour DNA
•    Circulating Tumour Cells (CTC)
•    Extracellular Vesicles
•    Others
Circulating tumour DNA is one of the most analysed biomarkers due to its capability of detecting cancer in earlier stages and prediction of cancer recurrence. CT-DNA and a combination of various biomarker analysis have provided sensitivity ranging from 69% to 98% for five different types of cancer according to a study by Cohen et al. These are the reasons that this market segment will receive good traction during the forecast period. Exosomes, which are small vesicles, were thought to be as waste disposal units initially. But recent researches suggest that they play an important role in the initiation of cancer and also in its progression and metastasis. Due to this new revelation, this market segment will get a significant amount of traction during the forecast period and especially in the developed economy market regions like North America and Europe as they adopt newer technologies with ease. 

By End User
•    Hospitals
•    Cancer Research Centres
•    Diagnostic Laboratories
Hospitals dominate this market segment due to the provision of advanced infrastructure and introduction of multi-speciality hospitals. It is expected that they will dominate the global market in the forecast period as well. 

Liquid Biopsy Market Leading Companies:

  • Biocept Inc.
  • Qiagen N.V.
  • Roche Diagnostics.
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Menarini-Silicon Biosystems.
  • Trovagene Inc.
  • Guardant Health, Inc.
  • Mdxhealth SA.
  • Genomic Health Inc.

Biocept’s Target Selector liquid biopsy follows all the clinical regulations listed by the National Comprehensive Cancer Network (NCCN) and thus focusses on clinically-actionable cancer biomarkers that will lead to an efficient tumour identification and treatment which will provide them higher traction in the market during the forecast period.  

Recent Developments:

1. Bio-Rad Laboratories

  • Advancements in CTC Detection: In March 2024, Bio-Rad launched validated antibodies designed for rare cell and circulating tumor cell (CTC) enumeration, improving the precision of cancer diagnostics and monitoring. 

2. Roche

  • Roche offers the FoundationOne Liquid test, a comprehensive liquid biopsy that analyzes circulating tumor DNA (ctDNA) from blood samples. This test identifies 70 of the most commonly mutated genes in solid tumors, including microsatellite instability, aiding in personalized cancer treatment decisions. 

Objectives of the Study:
•     To provide with an exhaustive analysis on the Global Liquid Biopsy Market by Biomarker Type, by End-User, and by Region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and Rest of the World
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
•    Profiling of companies to evaluate their market shares, strategies, financials and core competencies 

 

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com